J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA ...
pharmaphorum5d
J&J throws the gauntlet down to AZ with new survival data
Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with EGFR-mutated non-small cell lung cancer (NSCLC ...
Benzinga.com6d
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
Rybrevant plus Lazcluze extended overall survival beyond three years in first-line EGFR-mutated NSCLC, surpassing osimertinib’s 36.7 months. 56% of patients on Rybrevant plus Lazcluze were alive ...
Johnson & Johnson’s rybrevant plus lazcluze featured in lung cancer presentation
Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...
FiercePharma6d
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace AstraZeneca’s Tagrisso as the new standard of care in first-line EGFR ...